COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Budesonide Foam Versus Placebo for Prevention of Acute Radiation Proctitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00828230
Recruitment Status : Terminated (Study was prematurely stopped due to slow recruitment after 17 of 32 anticipated patients were recruited.)
First Posted : January 23, 2009
Last Update Posted : January 30, 2012
Information provided by (Responsible Party):
Dr. Falk Pharma GmbH

Brief Summary:
To proof the superiority of an 8-week rectal treatment with once-daily 2 mg budesonide versus placebo for the prevention of acute radiation proctitis, and to evaluate the occurrence of chronic radiation proctitis 1 year after start of radiation therapy.

Condition or disease Intervention/treatment Phase
Radiation Proctitis Drug: budesonide Drug: Placebo foam Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 17 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Randomised, Double-blind, Placebo-controlled, Multicentre, Comparative Phase II Pilot Study on the Efficacy and Tolerability of an 8-week Rectal Treatment With 2 mg Budesonide or Placebo for the Prevention of Acute Radiation Proctitis
Study Start Date : September 2008
Actual Primary Completion Date : August 2011
Actual Study Completion Date : October 2011

Resource links provided by the National Library of Medicine

Drug Information available for: Budesonide

Arm Intervention/treatment
Experimental: 1
2mg rectal budesonide per day for 8 weeks
Drug: budesonide
One application of 2mg budesonide once daily for 8 weeks
Other Name: Budenofalk rectal foam

Placebo Comparator: 2
One application of placebo foam once daily for 8 weeks
Drug: Placebo foam
One application of placebo foam once daily for 8 weeks
Other Name: placebo

Primary Outcome Measures :
  1. Proportion of patients developing radiation proctitis during treatment or need rescue medication [ Time Frame: within 8 weeks ]

Secondary Outcome Measures :
  1. Time to occurrence of acute radiation proctitis [ Time Frame: During 8 weeks ]
  2. Time to occurrence of chronic radiation proctitis [ Time Frame: Within 1 year ]
  3. Adverse Events (AEs) [ Time Frame: During 8 weeks of treatment ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Signed informed consent,
  • Men aged at least 18 years,
  • Patients with ECOG performance status <= 2 or Karnofsky Performance Status Scale >= 70%,
  • Estimated life expectancy more than 3 years,
  • Diagnosis of prostate carcinoma,
  • Indication for local RT in patients with prostatic cancer.

Exclusion Criteria:

  • Crohn's disease, indeterminate colitis, ulcerative colitis, microscopic colitis (i.e., collagenous colitis and lymphocytic colitis),
  • Severe or symptomatic ischaemic colitis at baseline,
  • Grade III internal haemorrhoids at baseline,
  • High risk patients needing extended radiation therapy,
  • Acute EORTC/RTOG lower GI toxicity score of >=1 at baseline,
  • Bacterial, amoebic, fungal, or viral infections of the gut,
  • Tuberculosis, hypertension, infection, diabetes mellitus (included familiarly predisposition), active peptic ulcer, osteoporosis, glaucoma, or cataract, if careful medical monitoring is not ensured,
  • Portal hypertension or liver cirrhosis,
  • Abnormal hepatic function (ALT, AST or AP > 2.5 x ULN),
  • Known intolerance/hypersensitivity/resistance to study drug or drugs of similar chemical structure or pharmacological profile, or to any of the other constituents of the study drug,
  • Participation in another clinical trial within the last 30 days, simultaneous participation in another clinical trial, or previous participation in this trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00828230

Layout table for location information
Klinik für Radioonkologie und Strahlentherapie - Klinikum Braunschweig
Braunschweig, Germany, 38114
Strahlentherapie, St. Vincentius-Kliniken gAG
Karlsruhe, Germany, 76135
Strahlentherapie, Klinikum Mutterhaus der Borromäerinnen
Trier, Germany, 54290
Sponsors and Collaborators
Dr. Falk Pharma GmbH
Layout table for investigator information
Study Director: Ralph Mueller, Dr Dr. Falk Pharma GmbH
Layout table for additonal information
Responsible Party: Dr. Falk Pharma GmbH Identifier: NCT00828230    
Other Study ID Numbers: BUF-17/RAP
EudraCT No.: 2007-002082-13
First Posted: January 23, 2009    Key Record Dates
Last Update Posted: January 30, 2012
Last Verified: January 2012
Keywords provided by Dr. Falk Pharma GmbH:
acute radiation proctitis
late radiation proctitis
Prevention of acute radiation proctitis
Prevention of late radiation proctitis
Additional relevant MeSH terms:
Layout table for MeSH terms
Gastrointestinal Diseases
Digestive System Diseases
Rectal Diseases
Intestinal Diseases
Anti-Inflammatory Agents
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Hormones, Hormone Substitutes, and Hormone Antagonists